Radiation therapy and serum salivary amylase in head and neck cancer
Metrics: PDF 502 views | HTML 919 views | ?
Francesca De Felice1, Mario Tombolini2, Angela Musella3, Francesco Marampon4, Vincenzo Tombolini1 and Daniela Musio1
1Department of Radiotherapy, Policlinico Umberto I, “Sapienza” University of Rome, Rome, Italy
2Department Organs of Sense, Policlinico Umberto I, “Sapienza”, University of Rome, Rome, Italy
3Department of Gynecology, Obstetrics and Urological Sciences, Policlinico Umberto I, “Sapienza” University of Rome, Rome, Italy
4Department of Biotechnological and Applied Clinical Sciences, Laboratory of Radiobiology, University of L'Aquila, L'Aquila, Italy
Francesca De Felice, email: email@example.com
Keywords: amylase, head and neck cancer, radiotherapy, dose, salivary glands
Received: May 07, 2017 Accepted: June 10, 2017 Published: June 28, 2017
Radiation therapy (RT) is a valid treatment option for head and neck cancer (HNC). The risk of RT-induced toxicities is significant, especially due to extended treatment fields. The raise in amylase activity is strictly dependent on the volume of salivary glands included in the irradiated target volume and it is firmly related to the dose. The aim of this review is to report the effects on salivary amylase activity after radiation exposure of salivary glands, in patients with HNC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.